Technical Analysis for INSY - Insys Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 4.96 3.77% 0.18
INSY closed up 3.77 percent on Friday, February 15, 2019, on 1.19 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical INSY trend table...

Date Alert Name Type % Chg
Feb 15 Weak + Overbought Other 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 15 Overbought Stochastic Strength 0.00%
Feb 15 Up 3 Days in a Row Strength 0.00%
Feb 15 Up 4 Days in a Row Strength 0.00%
Feb 14 New Uptrend Bullish 3.77%
Feb 14 NR7 Range Contraction 3.77%
Feb 14 Stochastic Reached Overbought Strength 3.77%
Feb 14 Weak + Overbought Other 3.77%
Feb 14 Inside Day Range Contraction 3.77%

Older signals for INSY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.
Medicine Cancer Pharmaceutical Chemical Compounds Organic Compounds Oncology Pharmaceutical Products Chemotherapy Cancer Treatments Antineoplastic Drugs Euphoriants Cancer Therapeutics Vomiting AIDS Cancer Therapy Paclitaxel Treating Cancer Chemotherapy Induced Nausea
Is INSY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.65
52 Week Low 3.35
Average Volume 913,470
200-Day Moving Average 6.8765
50-Day Moving Average 4.2932
20-Day Moving Average 4.1055
10-Day Moving Average 4.46
Average True Range 0.3872
ADX 26.77
+DI 32.5405
-DI 13.9839
Chandelier Exit (Long, 3 ATRs ) 3.8134
Chandelier Exit (Short, 3 ATRs ) 4.5416
Upper Bollinger Band 5.0483
Lower Bollinger Band 3.1627
Percent B (%b) 0.95
BandWidth 45.928632
MACD Line 0.1038
MACD Signal Line -0.0517
MACD Histogram 0.1555
Fundamentals Value
Market Cap 360.58 Million
Num Shares 72.7 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -22.55
Price-to-Sales 2.18
Price-to-Book 1.57
PEG Ratio -0.62
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.33
Resistance 3 (R3) 5.29 5.13 5.27
Resistance 2 (R2) 5.13 5.04 5.15 5.25
Resistance 1 (R1) 5.05 4.98 5.09 5.08 5.23
Pivot Point 4.89 4.89 4.91 4.91 4.89
Support 1 (S1) 4.80 4.79 4.85 4.84 4.69
Support 2 (S2) 4.64 4.74 4.66 4.67
Support 3 (S3) 4.56 4.64 4.65
Support 4 (S4) 4.59